血管加压药、肠内营养与非闭塞性肠系膜缺血的关联评估挑战
本文综述了评估血管加压药、肠内营养(EN)与非闭塞性肠系膜缺血(NOMI)关联的挑战。诊断依赖CT血管造影,缺乏随机对照试验证实关联;观察性数据显示低剂量血管加压药下谨慎EN可能可行,但指南对启动EN的血管加压药阈值描述有限。药师可参与个体化营养决策。
要点
- NOMI在重症患者中不常见但严重,诊断困难且缺乏高质量比较数据。
- 观察性数据显示低剂量血管加压药下谨慎EN可能可行,但血流动力学稳定定义不一。
- 指南建议未控制休克时暂停EN,但对启动EN的血管加压药阈值细节有限。
核心结论
- NOMI在重症患者中不常见但严重,血管加压药、EN与NOMI的关系因诊断挑战和高质量比较数据有限仍不确定,临床决策应个体化并警惕高危患者。
研究设计与样本
- 本文为综述,评估血管加压药、肠内营养与非闭塞性肠系膜缺血关联的挑战,并讨论药师在血流动力学不稳定时支持个体化营养决策的作用。
主要发现
- 实验和观察性数据提示血管加压药可能减少肠系膜血流,药物警戒分析显示几种血管活性药物与急性肠系膜缺血存在关联,但缺乏随机对照试验确立这些关联。
- 评估休克患者早期EN的证据显示肠道或肠系膜缺血报告率低(一般为0%-2%)。
- 大型随机试验发现全剂量EN组胃肠道并发症(包括罕见的肠缺血病例)发生率更高,但EN组与肠外营养(PN)组死亡率相似。
- 观察性数据提示较低血管加压药剂量下谨慎EN可能可行,但血流动力学稳定的定义各异。
关键数值与推荐
- 当前指南建议未控制休克时暂停EN,但对启动EN或调整剂量的血管加压药阈值提供细节有限。
临床怎么用
- 药师可评估血管加压药暴露、识别可能增加胃肠道不耐受或缺血担忧的患者特异性因素,并参与EN启动、推进和再评估的跨专业决策。
局限性
- 诊断困难(早期识别困难,体征非特异如肠梗阻、腹痛和乳酸酸中毒),且缺乏高质量比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Acute mesenteric ischemia is a potentially life-threatening condition resulting from thromboembolic occlusion or nonocclusive mechanisms such as vasospasm and excessive vasoconstriction. Nonocclusive mesenteric ischemia (NOMI) is of particular concern in critically ill patients receiving vasopressors and enteral nutrition (EN). This paper reviews the challenges in evaluating associations among vasopressors, EN, and NOMI and discusses the pharmacist's role in supporting patient-specific nutrition decisions during hemodynamic instability. SUMMARY: Mesenteric ischemia most commonly involves the superior mesenteric artery and carries high mortality. Diagnosis relies primarily on computed tomographic angiography because early recognition is difficult due to nonspecific signs such as ileus, abdominal pain, and lactic acidosis. Experimental and observational data suggest vasopressors may reduce mesenteric blood flow, with pharmacovigilance analyses demonstrating associations between several vasoactive agents and acute mesenteric ischemia. However, randomized controlled trials to establish these associations are lacking. Evidence evaluating early EN in patients with shock shows low reported rates of bowel or mesenteric ischemia (generally 0%-2%). Large randomized trials found higher rates of gastrointestinal complications, including rare cases of bowel ischemia, with full-dose EN but found similar mortality in patients receiving EN and those receiving parenteral nutrition (PN). Observational data suggest cautious EN may be feasible at lower vasopressor doses, though definitions of hemodynamic stability vary. Current guidelines recommend withholding EN during uncontrolled shock but provide limited detail regarding vasopressor thresholds for EN initiation or dosing modifications. Pharmacists can contribute by evaluating vasopressor exposure, recognizing patient-specific factors that may increase concern for gastrointestinal intolerance or ischemia, and participating in interprofessional decisions regarding EN initiation, advancement, and reassessment. CONCLUSION: NOMI is uncommon but serious in critically ill patients. The relationships between vasopressors, EN, and NOMI remain uncertain due to diagnostic challenges and limited high-quality comparative data. Clinical decisions should be individualized, with vigilance in at-risk patients.
引用
- Bingham AL, Erstad BL. Challenges in evaluating associations among vasopressors, enteral nutrition, and nonocclusive mesenteric ischemia. Am J Health Syst Pharm. 2026. PMID: 42659644. doi:10.1093/ajhp/zxag251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。